178

Immunology & Rheumatology
Focuses on rheumatic and immune diseases.
Sub Categories on Immunology & Rheumatology
Latest Articles
Lupus, rheumatoid arthritis tied to higher risk for adverse obstetric, birth outcomes

Lupus, rheumatoid arthritis tied to higher risk for adverse obstetric, birth outcomes

by Lori SolomonWomen with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants experience higher rates of adverse obstetric and birth outcomes, according to a study publis

Lupus, rheumatoid arthritis tied to higher risk for adverse obstetric, birth outcomes

by Lori SolomonWomen with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants experience higher rates of adverse obstetric and birth outcomes, according to a study publis
Higher incidence of edema with bacteriuria in C1-INH-HAE

Higher incidence of edema with bacteriuria in C1-INH-HAE

(HealthDay)—For patients with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE), those with bacteriuria have a higher number of edematous attacks, according to a study published online

Higher incidence of edema with bacteriuria in C1-INH-HAE

(HealthDay)—For patients with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE), those with bacteriuria have a higher number of edematous attacks, according to a study published online
CAR-T therapy modifications provide new promise for cancer immunotherapies

CAR-T therapy modifications provide new promise for cancer immunotherapies

by King's College LondonCredit: CC0 Public DomainNew research led by Dr. John Maher, from the School of Cancer & Pharmaceutical Sciences, working for Leucid Bio and with biotech company L

CAR-T therapy modifications provide new promise for cancer immunotherapies

by King's College LondonCredit: CC0 Public DomainNew research led by Dr. John Maher, from the School of Cancer & Pharmaceutical Sciences, working for Leucid Bio and with biotech company L
COVID-19, MIS-C and Kawasaki disease share same immune response

COVID-19, MIS-C and Kawasaki disease share same immune response

by University of California - San DiegoUC San Diego researchers summarize the similarities and differences between COVID-19, MIS-C and Kawasaki disease, three conditions unified by the same immun

COVID-19, MIS-C and Kawasaki disease share same immune response

by University of California - San DiegoUC San Diego researchers summarize the similarities and differences between COVID-19, MIS-C and Kawasaki disease, three conditions unified by the same immun
Innovative software improves chronic rheumatic disease care

Innovative software improves chronic rheumatic disease care

(HealthDay)—For patients with chronic rheumatic disease, innovative software that aggregates, stores, and displays information can improve quality of care, according to research published online Nov.

Innovative software improves chronic rheumatic disease care

(HealthDay)—For patients with chronic rheumatic disease, innovative software that aggregates, stores, and displays information can improve quality of care, according to research published online Nov.
FDA approves 1st drug for moderate and severe eczema cases

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved
TAp63: A new protein drug target for rheumatoid arthritis

TAp63: A new protein drug target for rheumatoid arthritis

by Chiba UniversityGraphical abstract. Credit:JCI Insight(2023). DOI: 10.1172/jci.insight.164778Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint deterioration. The

TAp63: A new protein drug target for rheumatoid arthritis

by Chiba UniversityGraphical abstract. Credit:JCI Insight(2023). DOI: 10.1172/jci.insight.164778Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint deterioration. The
Inflammation can lead to circadian sleep disorders

Inflammation can lead to circadian sleep disorders

by Northwestern UniversityCredit: CC0 Public DomainInflammation, which is the root cause of autoimmune disorders including arthritis, Type 1 diabetes, irritable bowel syndrome and Crohn's dis

Inflammation can lead to circadian sleep disorders

by Northwestern UniversityCredit: CC0 Public DomainInflammation, which is the root cause of autoimmune disorders including arthritis, Type 1 diabetes, irritable bowel syndrome and Crohn's dis
A protein that controls inflammation

A protein that controls inflammation

by VIB (the Flanders Institute for Biotechnology)Credit: CC0 Public DomainA study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical

A protein that controls inflammation

by VIB (the Flanders Institute for Biotechnology)Credit: CC0 Public DomainA study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical
Meta-analysis quantifies lifestyle factors accounting for RA incidence

Meta-analysis quantifies lifestyle factors accounting for RA incidence

(HealthDay)—Nearly one-third of rheumatoid arthritis (RA) incidence is attributed to smoking, excess body mass index, and low alcohol consumption, according to a study published online Jan. 26 in&nbsp

Meta-analysis quantifies lifestyle factors accounting for RA incidence

(HealthDay)—Nearly one-third of rheumatoid arthritis (RA) incidence is attributed to smoking, excess body mass index, and low alcohol consumption, according to a study published online Jan. 26 in&nbsp
Minority patients with rheumatic diseases have worse COVID-19 outcomes

Minority patients with rheumatic diseases have worse COVID-19 outcomes

by American College of RheumatologyCredit: CC0 Public DomainNew research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic

Minority patients with rheumatic diseases have worse COVID-19 outcomes

by American College of RheumatologyCredit: CC0 Public DomainNew research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic
TNF inhibitors may not modify polyarticular JIA disease process

TNF inhibitors may not modify polyarticular JIA disease process

(HealthDay)—For children with polyarticular juvenile idiopathic arthritis (JIA), discontinuing medications is challenging, with high relapse rates, especially after discontinuation of tumor necrosis f

TNF inhibitors may not modify polyarticular JIA disease process

(HealthDay)—For children with polyarticular juvenile idiopathic arthritis (JIA), discontinuing medications is challenging, with high relapse rates, especially after discontinuation of tumor necrosis f